BAY 1082439

Drug Profile

BAY 1082439

Alternative Names: BAY1082439

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Bayer
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Bone metastases

Most Recent Events

  • 14 Apr 2016 Preclinical trials in Bone metastases in Germany (unspecified route) before April 2016
  • 14 Apr 2016 Pharmacodynamics data from a preclinical trial in Bone metastases presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 09 Oct 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA and Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top